Literature DB >> 21628537

Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility.

Kelley R Healey1, Santosh K Katiyar, Mariana Castanheira, Michael A Pfaller, Thomas D Edlind.   

Abstract

Echinocandins, including caspofungin (CSP) and micafungin (MCF), are highly active versus Candida glabrata (MIC of ≤0.06 μg/ml). True resistance (MIC of ≥1 μg/ml) is a rare event and strictly associated with mutations in β-1,3-glucan synthase gene FKS1 or FKS2. In contrast, we show here that mutants exhibiting reduced susceptibility to CSP (CRS; MICs of 0.12 to 0.5 μg/ml) are readily selected in vitro and, paradoxically, demonstrate increased susceptibility to MCF (MIS) ranging from 4- to 32-fold. CRS-MIS mutants were generated from all 10 C. glabrata strains tested and were tentatively identified within a collection of clinical isolates. Intriguingly, sequencing and gene disruption demonstrated that CRS-MIS is Fks independent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628537      PMCID: PMC3147630          DOI: 10.1128/AAC.00044-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Fungal beta(1,3)-D-glucan synthesis.

Authors:  C M Douglas
Journal:  Med Mycol       Date:  2001       Impact factor: 4.076

2.  Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Authors:  John D Cleary; Guillermo Garcia-Effron; Stanley W Chapman; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 3.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

4.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 5.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Authors:  M A Pfaller; D J Diekema; D Andes; M C Arendrup; S D Brown; S R Lockhart; M Motyl; D S Perlin
Journal:  Drug Resist Updat       Date:  2011-02-24       Impact factor: 18.500

6.  Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.

Authors:  John-Paul Vermitsky; Kelly D Earhart; W Lamar Smith; Ramin Homayouni; Thomas D Edlind; P David Rogers
Journal:  Mol Microbiol       Date:  2006-06-27       Impact factor: 3.501

7.  Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast.

Authors:  Thomas D Edlind; Karl W Henry; John-Paul Vermitsky; Merritt P Edlind; Shriya Raj; Santosh K Katiyar
Journal:  Curr Genet       Date:  2005-09-14       Impact factor: 3.886

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection.

Authors:  John-Paul Vermitsky; Matthew J Self; Sean G Chadwick; Jason P Trama; Martin E Adelson; Eli Mordechai; Scott E Gygax
Journal:  J Clin Microbiol       Date:  2008-02-27       Impact factor: 5.948

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

View more
  15 in total

1.  Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.

Authors:  Mariana Castanheira; Leah N Woosley; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

Review 2.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 3.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

4.  Sphingolipids mediate differential echinocandin susceptibility in Candida albicans and Aspergillus nidulans.

Authors:  Kelley R Healey; Krishna K Challa; Thomas D Edlind; Santosh K Katiyar
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

5.  Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

6.  Epidemiology of echinocandin resistance in Candida.

Authors:  Nina T Grossman; Tom M Chiller; Shawn R Lockhart
Journal:  Curr Fungal Infect Rep       Date:  2014-09-21

7.  CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.

Authors:  Kelley R Healey; Santosh K Katiyar; Shriya Raj; Thomas D Edlind
Journal:  Mol Microbiol       Date:  2012-08-22       Impact factor: 3.501

8.  Echinocandin Resistance in Candida.

Authors:  David S Perlin
Journal:  Clin Infect Dis       Date:  2015-12-01       Impact factor: 9.079

9.  Polymorphism of Polymeric Amino Acid Regions in Fungal Proteins and Correlation with Altered Echinocandin and Azole Susceptibility.

Authors:  Krishna Challa; Tom Edlind; Santosh Katiyar
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

10.  Spontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrata.

Authors:  Ryan K Shields; Ellen G Kline; Kelley R Healey; Milena Kordalewska; David S Perlin; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.